Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 81

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 81
---
 smoking-related diseases—such as lung cancer, cardiovascular issues, and respiratory disorders—continues to push individuals toward cessation. Public health campaigns by organizations like the World Health Organization (“WHO”) and local governments amplify this trend (Source: http://www.tocaccofreekids.org). Policies such as higher tobacco taxes, smoking bans in public spaces, and subsidized cessation programs are significant catalysts. For instance, the UK aims for a smoke-free England by 2030, while countries like Japan have raised tobacco costs to encourage quitting. Innovations like smart nicotine patches, digital cessation apps, and personalized quit programs enhance effectiveness and accessibility. E-cigarettes and heatnot-burn products also offer alternatives that appeal to smokers transitioning away from traditional cigarettes. In the U.S. alone, millions of smokers attempt to quit annually, with similar trends globally, increasing demand for cessation products and services.

Product Segments

Nicotine Replacement Therapy (NRT):Dominates the market with products like gums, patches, lozenges, inhalers, and sprays. NRT is favored for its proven efficacy in reducing withdrawal symptoms and is expected to grow at a CAGR of around 9-15% through 2034 (Source: https://www.factmr.com) .

E-Cigarettes: A rapidly expanding segment due to their popularity as a less harmful alternative to traditional smoking. This category is projected to grow at a CAGR of up to 19% according to some forecasts, driven by product innovation and consumer acceptance (Source: https://www.precedenceresearch.com).

Prescription Medications: Drugs like varenicline (Chantix) and bupropion (Zyban) remain key options, though generics may temper revenue growth for branded versions.

Digital and Behavioral Therapies: Mobile apps and counseling services are gaining traction, offering tailored support and contributing to market diversification.

Weight Gain Associated With Smoking Cessation

Weight gain is a common concern for people who quit smoking, and clinical studies have explored this phenomenon in detail. The market for addressing weight gain during smoking cessation is closely tied to the broader smoking cessation and nicotine de-addiction market, which includes products and drugs aimed at helping individuals quit smoking while managing associated side effects like weight gain (Source https://pmc.ncbi.nlm.nih.gov). Below is an overview based on available data and trends:

Market Size Estimates:

The global smoking cessation and nicotine de-addiction market was valued at approximately $25.5 billion in 2024 and is projected to grow at